Basic Information
| LncRNA/CircRNA Name | CCAT2 |
| Synonyms | CCAT2, LINC00873, NCCP1 |
| Region | GRCh38_8:127400399-127402150 |
| Ensemble | ENSG00000280997 |
| Refseq | NR_109834 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot etc. |
| Sample | osteosarcoma tissues, cell line (SAOS-2, MG63, U2-OS and Nhost) |
| Expression Pattern | up-regulated |
| Function Description | We demonstrated that lncRNA CCAT2 expression was significantly upregulated in OS tissues compared to adjacent normal bone tissues. Higher lncRNA CCAT2 expression positively associated with larger tumor size, advanced tumor stage and poor overall survival (OS) rate of patients. In vitro, knockdown of lncRNA CCAT2 suppressed cell proliferation and colony formation ability. In contrast, overexpression of lncRNA CCAT2 showed promoting cell proliferation effects in OS. Also, we found that knockdown of lncRNA CCAT2 inhibited GSK3B/B-catenin signaling by reducing p-GSK3B and B-catenin expression, but increasing GSK3B expression. |
| Pubmed ID | 29863240 |
| Year | 2018 |
| Title | LncRNA CCAT2 enhances cell proliferation via GSK3?/?-catenin signaling pathway in human osteosarcoma. |
External Links
| Links for CCAT2 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |